Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the ...

In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Further information This topic is currently suspended. Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for ...

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.